GLOBAL PARTNERS LP 9.50% FIXED RATE CUM RED PERP SER B

GLP-B
25.4800.00% ( 0.000 )
Closed: Jul 29, 16:00:00 (EDT)

GLOBAL PARTNERS LP 9.50% FIXED RATE CUM RED PERP SER B (GLP-B)

Open
--
High
--
Low
--
Prev. Close
25.480
Volume
0
Turnover
0
Avg Price
--
Bid/Ask Ratio
--
Amplitude
--
52wk High
25.630
Volume Ratio
0.00
Turnover Ratio
--
52wk Low
23.717
Float Mkt Cap
--
Market CapUSD
--
P/ETTM
--
P/EDynamic
--
P/EStatic
--
EPSTTM
--
EPSDynamic
--
EPSStatic
--
BVPS
--
P/B
--
Circulating Supply
0.00
Dividend YieldTTM
--
DividendTTM
--
Shares
0.00
Min lot size
1
Currency
USD

Bullish vs. Bearish — Last 3 Months

1 followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • H
    Hardik Shah

    📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Viking Therap(VKTX.US) Viking Therapeutics Launches Phase 1 Trial for New Weight-Loss Drug VK3019

    👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

    ➤ 𝐕𝐢𝐤𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 initiated a 𝐏𝐡𝐚𝐬𝐞 𝟏 trial of weight-loss candidate VK3019.

    ➤ VK3019 is a 𝐝𝐮𝐚𝐥 𝐚𝐦𝐲𝐥𝐢𝐧 and 𝐜𝐚𝐥𝐜𝐢𝐭𝐨𝐧𝐢𝐧 receptor agonist (DACRA).

    ➤ Trial follows 𝐅𝐃𝐀 clearance of VK3019's Investigational New Drug application.

    ➤ Study will evaluate 𝐬𝐚𝐟𝐞𝐭𝐲, 𝐭𝐨𝐥𝐞𝐫𝐚𝐛𝐢𝐥𝐢𝐭𝐲, and pharmacokinetics in adults with BMI ≥ 30.

    ➤ Exploratory assessments include changes in 𝐛𝐨𝐝𝐲 𝐰𝐞𝐢𝐠𝐡𝐭 after a single dose.

    ➤ Preclinical data showed up to 𝟖% 𝐛𝐨𝐝𝐲-𝐰𝐞𝐢𝐠𝐡𝐭 reduction within 72 hours in animal studies.

    ➤ Viking is also conducting 𝐏𝐡𝐚𝐬𝐞 𝟑 VANQUISH trials for obesity drug VK2735.

    ➤ Company plans to launch a 𝐏𝐡𝐚𝐬𝐞 𝟑 trial of oral VK2735 later in 2026.

    👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:

    ➤ VK3019 expands Viking's pipeline in the rapidly growing 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 treatment market.

    ➤ DACRA therapies could complement 𝐆𝐋𝐏-𝟏 and GLP-1/GIP weight-loss medicines.

    ➤ Success could provide additional 𝐥𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐰𝐞𝐢𝐠𝐡𝐭-𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 options for patients.

    👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

    ➤ "The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧, Ph.D., Chief Executive Officer of Viking Therapeutics.

    ➤ "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧.

    ➤ "Broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧.

  • T
    Tom Nash Updates

    GLP 1 demand is exploding because everyone wants the easy button, quick fix, no effort, no discipline

    I dropped 50 pounds in 5 months

    No drugs

    Just sleep, clean diet, resistance training, consistency

    There is no secret, just boring execution every single day

    If I can do it, anyone can

    This is not a flex, this is proof that discipline still works

  • M
    Marina Bay

    $Hims & Hers Health(HIMS.US) holds leading scale in US direct-to-consumer personalized telehealth (~2x the size of many #2 players).

    Core moat includes data flywheel (labs with 130+ biomarkers), high customer trust/brand, low churn via subscriptions, and supplier networks. Competitors include Ro/Roman, traditional telehealth, and branded pharma direct channels.

    Threats from GLP-1 price competition and compounding regulations are being actively mitigated via branded pivots and diversification. Market share continues expanding in core categories.

    @Bridge Buzz SG

    NewDiscussionZones